Iatrogenic keratopathy secondary to multiple myeloma treatment with belantamab mafodotin

被引：1

作者：

Menardais, B. ^{[1
]}

Soethoudt, M. ^{[1
]}

Espargilliere, D. ^{[1
]}

Mouriaux, F. ^{[1
]}

机构：

[1] CHU Rennes, Serv Ophtalmol, F-35033 Rennes, France

来源：

JOURNAL FRANCAIS D OPHTALMOLOGIE | 2021年 / 44卷 / 05期

关键词：

D O I：

10.1016/j.jfo.2020.07.008

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

引用

页码：766 / 768

页数：3

共 3 条

[1]

ANSM, 2020, PROT UT THER REC INF

[2] Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study [J].

Lonial, Sagar ;

Lee, Hans C. ;

Badros, Ashraf ;

Trudel, Suzanne ;

Nooka, Ajay K. ;

Chari, Ajai ;

Abdallah, Al-Ola ;

Callander, Natalie ;

Lendvai, Nikoletta ;

Sborov, Douglas ;

Suvannasankha, Attaya ;

Weisel, Katja ;

Karlin, Lionel ;

Libby, Edward ;

Arnulf, Bertrand ;

Facon, Thierry ;

Hulin, Cyrille ;

Kortum, K. Martin ;

Rodriguez-Otero, Paula ;

Usmani, Saad Z. ;

Hari, Parameswaran ;

Baz, Rachid ;

Hang Quach ;

Moreau, Philippe ;

Voorhees, Peter M. ;

Gupta, Ira ;

Hoos, Axel ;

Zhi, Eric ;

Baron, January ;

Piontek, Trisha ;

Lewis, Eric ;

Jewell, Roxanne C. ;

Dettman, Elisha J. ;

Popat, Rakesh ;

Esposti, Simona Degli ;

Opalinska, Joanna ;

Richardson, Paul ;

Cohen, Adam D. .

LANCET ONCOLOGY, 2020, 21 (02) :207-221

[3] Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial [J].

Popat, Rakesh ;

Warcel, Dana ;

O'Nions, Jenny ;

Cowley, Anna ;

Smith, Sasha ;

Tucker, William R. ;

Yong, Kwee ;

Esposti, Simona Degli .

HAEMATOLOGICA, 2020, 105 (05) :E261-E263

← 1 →